JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 84 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $161,000 | -14.8% | 24,700 | 0.0% | 0.00% | – |
| Q2 2018 | $189,000 | -65.8% | 24,700 | 0.0% | 0.00% | -100.0% |
| Q1 2018 | $552,000 | +75.2% | 24,700 | 0.0% | 0.00% | – |
| Q4 2017 | $315,000 | +50.7% | 24,700 | +84.3% | 0.00% | – |
| Q3 2017 | $209,000 | +11.2% | 13,400 | 0.0% | 0.00% | – |
| Q2 2017 | $188,000 | – | 13,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |